Biomarkers in Lung Diseases : from Pathogenesis to Prediction to New Therapies Lung tissue proteomics identifies elevated transglutaminase 2 levels in stable chronic obstructive pulmonary disease
暂无分享,去创建一个
S. Ohlmeier | P. Nieminen | Jing Gao | T. Kanerva | M. Rönty | T. Toljamo | U. Bergmann | W. Mazur | V. Pulkkinen | Jing Gao | Tinja Kanerva | Tuula I. Toljamo | Ulrich Bergmann
[1] E. Walters,et al. β-Actin and GAPDH housekeeping gene expression in asthmatic airways is variable and not suitable for normalising mRNA levels , 2002, Thorax.
[2] P. Sterk,et al. Sputum induction , 2002, European Respiratory Journal.
[3] R. Stockley,et al. α1-Antitrypsin deficiency • 3: Clinical manifestations and natural history , 2004, Thorax.
[4] Stefano Guerra,et al. Asthma as a risk factor for COPD in a longitudinal study. , 2004, Chest.
[5] M. Lenter,et al. Proteomic study of human bronchoalveolar lavage fluids from smokers with chronic obstructive pulmonary disease by combining surface‐enhanced laser desorption/ionization‐mass spectrometry profiling with mass spectrometric protein identification , 2005, Proteomics.
[6] V. Kinnula,et al. Increased oxidative stress in asymptomatic current chronic smokers and GOLD stage 0 COPD , 2006, Respiratory research.
[7] R. Abboud,et al. Stability of housekeeping genes in alveolar macrophages from COPD patients , 2006, European Respiratory Journal.
[8] Y. Soini,et al. Modulation of glutaredoxin in the lung and sputum of cigarette smokers and chronic obstructive pulmonary disease , 2006, Respiratory research.
[9] L. Pannell,et al. Protein expression in sputum of smokers and chronic obstructive pulmonary disease patients: a pilot study by CapLC-ESI-Q-TOF. , 2007, Journal of proteome research.
[10] Per Broberg,et al. Protein expression patterns associated with progression of chronic obstructive pulmonary disease in bronchoalveolar lavage of smokers. , 2007, Clinical chemistry.
[11] S. Ohlmeier,et al. Proteomics of human lung tissue identifies surfactant protein A as a marker of chronic obstructive pulmonary disease. , 2008, Journal of proteome research.
[12] V. Villella,et al. Tissue Transglutaminase Activation Modulates Inflammation in Cystic Fibrosis via PPARγ Down-Regulation1 , 2008, The Journal of Immunology.
[13] Xiaohang Zhao,et al. Quantitative proteomic signature of liver cancer cells: tissue transglutaminase 2 could be a novel protein candidate of human hepatocellular carcinoma. , 2008, Journal of proteome research.
[14] S. Merali,et al. Cigarette smoke induces an unfolded protein response in the human lung: a proteomic approach. , 2008, American journal of respiratory cell and molecular biology.
[15] D. Porteous,et al. Sputum proteomics in inflammatory and suppurative respiratory diseases. , 2008, American journal of respiratory and critical care medicine.
[16] Eun Joo Lee,et al. Proteomic analysis in lung tissue of smokers and COPD patients. , 2009, Chest.
[17] P. Metcalf,et al. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history , 2009, European Respiratory Journal.
[18] S. Ohlmeier,et al. Proteomic approaches for studying human parenchymal lung diseases , 2009, Expert review of proteomics.
[19] P. Howarth,et al. Identification of lipocalin and apolipoprotein A1 as biomarkers of chronic obstructive pulmonary disease. , 2010, American journal of respiratory and critical care medicine.
[20] P. Nieminen,et al. Early detection of COPD combined with individualized counselling for smoking cessation: A two-year prospective study , 2010, Scandinavian journal of primary health care.
[21] S. Ohlmeier,et al. Proteomic studies on receptor for advanced glycation end product variants in idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease , 2010, Proteomics. Clinical applications.
[22] W. Henderson,et al. Transglutaminase 2, a Novel Regulator of Eicosanoid Production in Asthma Revealed by Genome-Wide Expression Profiling of Distinct Asthma Phenotypes , 2010, PloS one.
[23] S. Ohlmeier,et al. Elevation of surfactant protein A in plasma and sputum in cigarette smokers , 2011, European Respiratory Journal.
[24] S. Jang,et al. Transglutaminase 2 as an independent prognostic marker for survival of patients with non-adenocarcinoma subtype of non-small cell lung cancer , 2011, Molecular Cancer.
[25] S. Ohlmeier,et al. Sputum proteomics identifies elevated PIGR levels in smokers and mild-to-moderate COPD. , 2012, Journal of proteome research.
[26] I. Martín-Loeches,et al. Critical COPD respiratory illness is linked to increased transcriptomic activity of neutrophil proteases genes , 2012, BMC Research Notes.
[27] V. Poletti,et al. The pathogenesis of COPD and IPF: Distinct horns of the same devil? , 2012, Respiratory Research.
[28] F. Martinez,et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.
[29] Rui M. M. Branca,et al. Quantitative proteomics profiling of primary lung adenocarcinoma tumors reveals functional perturbations in tumor metabolism. , 2013, Journal of Proteome Research.
[30] C. Greenberg,et al. TGM2 and implications for human disease: role of alternative splicing. , 2013, Frontiers in bioscience.
[31] S. Ohlmeier,et al. Distribution and levels of alpha‐1‐antitrypsin in the lung and plasma in smokers and chronic obstructive pulmonary disease , 2013, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[32] L. Paz-Ares,et al. Identification of proteomic signatures associated with lung cancer and COPD. , 2013, Journal of proteomics.
[33] Thomas H Thatcher,et al. Inhibition of transglutaminase 2, a novel target for pulmonary fibrosis, by two small electrophilic molecules. , 2014, American journal of respiratory cell and molecular biology.
[34] P. Nieminen,et al. Soluble receptor for advanced glycation end-products and progression of airway disease , 2014, BMC Pulmonary Medicine.
[35] Q. Hu,et al. Large-scale, ion-current-based proteomics investigation of bronchoalveolar lavage fluid in chronic obstructive pulmonary disease patients. , 2014, Journal of proteome research.
[36] Jesse D. Roberts,et al. Transglutaminase 2: a new player in bronchopulmonary dysplasia? , 2014, European Respiratory Journal.
[37] S. Ohlmeier,et al. Elevated sputum BPIFB1 levels in smokers with chronic obstructive pulmonary disease: a longitudinal study. , 2015, American journal of physiology. Lung cellular and molecular physiology.
[38] J. Keillor,et al. Inhibitors of tissue transglutaminase. , 2015, Trends in pharmacological sciences.
[39] P. Nieminen,et al. Clinical characteristics of COPD syndrome: A 6-year follow-up study of adult smokers , 2015, Annals of medicine.
[40] R. Savino,et al. Asthma and COPD proteomics: Current approaches and future directions , 2015, Proteomics. Clinical applications.